| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Omaciclovir (ABT 091; A-182091; H2G) is a novel and potent DNA polymerase inhibitor with the potential for the treatment of HSV infection. It is a nucleoside analog with antiviral activity. Omaciclovir is selectively phosphorylated by viral thymidine kinase to its monophosphate form and is further converted to the triphosphated form, which is an inhibitor of VZV DNA polymerase.
| ln Vitro |
Omaciclovir is a nucleoside analog that inhibits the varicella zoster virus (VZV), human herpesvirus 6, Epstein-Barr virus, and herpes simplex virus types 1 and 2. Omaciclovir is also effective against simian varicella virus-infected monkeys [1]. With EC50 values of 0.72 ± 0.1, 0.62 ± 0.2, 0.015 ± 0.004, 0.048 ± 0.023, 0.047 ± 0.004, 0.035 ± 0.022, and 0.016 ± 0.003 μM V for MRC-5 VZ -32, MeWo Molly, MeWo Emily, MeWo VZ11, and MeWo VZ30[1], respectively, omeaciclovir demonstrates antiviral activity against various human herpesviruses.
|
|---|---|
| References | |
| Additional Infomation |
Omaciclovir is an acyclic guanosine analog with activity against varicella zoster virus (VZV) and other members of the herpesvirus family. Omaciclovir is selectively phosphorylated by viral thymidine kinase to its monophosphate form and is further modified to a triphosphate, which is an inhibitor of VZV DNA polymerase.
|
| Molecular Formula |
C10H15N5O3
|
|---|---|
| Molecular Weight |
253.2578
|
| Exact Mass |
253.117
|
| CAS # |
124265-89-0
|
| PubChem CID |
135433609
|
| Appearance |
White to off-white solid powder
|
| Density |
1.68g/cm3
|
| Boiling Point |
637.8ºC at 760 mmHg
|
| Flash Point |
339.5ºC
|
| Vapour Pressure |
3.85E-17mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
18
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=NC2=C(N1C[C@@H](CCO)CO)N=C(NC2=O)N
|
| InChi Key |
SCBFBAWJWLXVHS-ZCFIWIBFSA-N
|
| InChi Code |
InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)3-6(4-17)1-2-16/h5-6,16-17H,1-4H2,(H3,11,13,14,18)/t6-/m1/s1
|
| Chemical Name |
2-amino-9-[(2R)-4-hydroxy-2-(hydroxymethyl)butyl]-1H-purin-6-one
|
| Synonyms |
H2G A-182091H 2G A182091(-)-2HM-HBG 2HMHBGABT 091 ABT091 ABT-091
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~230 mg/mL (~908.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5.75 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 57.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5.75 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 57.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5.75 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9485 mL | 19.7426 mL | 39.4851 mL | |
| 5 mM | 0.7897 mL | 3.9485 mL | 7.8970 mL | |
| 10 mM | 0.3949 mL | 1.9743 mL | 3.9485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
